HomeCompareARAFF vs JNJ

ARAFF vs JNJ: Dividend Comparison 2026

ARAFF yields 1025.64% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARAFF wins by $23506543.50M in total portfolio value
10 years
ARAFF
ARAFF
● Live price
1025.64%
Share price
$0.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23506543.53M
Annual income
$19,723,609,349,823.79
Full ARAFF calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — ARAFF vs JNJ

📍 ARAFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARAFFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARAFF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ARAFF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARAFF
Annual income on $10K today (after 15% tax)
$87,179.49/yr
After 10yr DRIP, annual income (after tax)
$16,765,067,947,350.22/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, ARAFF beats the other by $16,765,067,943,312.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARAFF + JNJ for your $10,000?

ARAFF: 50%JNJ: 50%
100% JNJ50/50100% ARAFF
Portfolio after 10yr
$11753271.78M
Annual income
$9,861,804,677,286.84/yr
Blended yield
83.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ARAFF
No analyst data
Altman Z
49.2
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARAFF buys
0
JNJ buys
0
No recent congressional trades found for ARAFF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARAFFJNJ
Forward yield1025.64%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$23506543.53M$30.5K
Annual income after 10y$19,723,609,349,823.79$4,749.88
Total dividends collected$23218513.75M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ARAFF vs JNJ ($10,000, DRIP)

YearARAFF PortfolioARAFF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$113,264$102,564.10$10,594$274.49+$102.7KARAFF
2$1,206,878$1,085,685.14$11,294$360.69+$1.20MARAFF
3$12,102,987$10,811,628.23$12,133$476.91+$12.09MARAFF
4$114,279,868$101,329,670.98$13,156$635.42+$114.27MARAFF
5$1,016,469,856$894,190,397.43$14,432$854.61+$1016.46MARAFF
6$8,520,740,273$7,433,117,527.67$16,056$1,162.76+$8520.72MARAFF
7$67,350,310,269$58,233,118,176.66$18,175$1,604.53+$67350.29MARAFF
8$502,243,173,894$430,178,341,906.41$21,009$2,252.68+$502243.15MARAFF
9$3,535,452,502,858$2,998,052,306,790.74$24,911$3,229.73+$3535452.48MARAFF
10$23,506,543,527,881$19,723,609,349,823.79$30,458$4,749.88+$23506543.50MARAFF

ARAFF vs JNJ: Complete Analysis 2026

ARAFFStock

Arafura Rare Earths Limited explores for and develops mineral properties in Australia. It focuses on the production of rare earth products, such as neodymium-praseodymium and mixed middle-heavy rare earths oxides. The company's principal property is the Nolans project, a rare earths-phosphate-uranium-thorium deposit that supplies neodymium and praseodymium products located in Northern Territory, Australia. It also engages in mining and associated infrastructure, and social and environmental feasibility evaluations. The company was formerly known as Arafura Resources Limited and changed its name to Arafura Rare Earths Limited in October 2022. Arafura Rare Earths Limited was incorporated in 1997 and is based in Perth, Australia.

Full ARAFF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this ARAFF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARAFF vs SCHDARAFF vs JEPIARAFF vs OARAFF vs KOARAFF vs MAINARAFF vs ABBVARAFF vs MRKARAFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.